What do systematic reviews say?

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs no treatment or placebo

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 565 participants
  Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs ethamsylate (control)

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs NSAIDs

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Progestogen 2

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 312 participants
  Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs herbal medicines

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 121 participants
  Low
• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs levonorgestrel intrauterine system

It is very uncertain whether antifibrinolytics changes menstrual blood loss: improvement in mean blood loss (PBAC score <… compared with levonorgestrel intrauterine system (very low certainty).

• Antifibrinolytics for heavy menstrual bleeding 2018 · Cochrane Headline outcomes only
  RR 0.43 [0.24, 0.77]
  1 study · 42 participants
  Very low